JP2015531377A5 - - Google Patents

Download PDF

Info

Publication number
JP2015531377A5
JP2015531377A5 JP2015534679A JP2015534679A JP2015531377A5 JP 2015531377 A5 JP2015531377 A5 JP 2015531377A5 JP 2015534679 A JP2015534679 A JP 2015534679A JP 2015534679 A JP2015534679 A JP 2015534679A JP 2015531377 A5 JP2015531377 A5 JP 2015531377A5
Authority
JP
Japan
Prior art keywords
vehicle
weight
liquid formulation
content
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015534679A
Other languages
English (en)
Japanese (ja)
Other versions
JP6248112B2 (ja
JP2015531377A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/062051 external-priority patent/WO2014052678A1/en
Publication of JP2015531377A publication Critical patent/JP2015531377A/ja
Publication of JP2015531377A5 publication Critical patent/JP2015531377A5/ja
Application granted granted Critical
Publication of JP6248112B2 publication Critical patent/JP6248112B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015534679A 2012-09-26 2013-09-26 アピキサバン液体製剤 Expired - Fee Related JP6248112B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261705943P 2012-09-26 2012-09-26
US61/705,943 2012-09-26
US201361773032P 2013-03-05 2013-03-05
US61/773,032 2013-03-05
PCT/US2013/062051 WO2014052678A1 (en) 2012-09-26 2013-09-26 Apixaban liquid formulations

Publications (3)

Publication Number Publication Date
JP2015531377A JP2015531377A (ja) 2015-11-02
JP2015531377A5 true JP2015531377A5 (https=) 2016-11-10
JP6248112B2 JP6248112B2 (ja) 2017-12-13

Family

ID=49447800

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015534679A Expired - Fee Related JP6248112B2 (ja) 2012-09-26 2013-09-26 アピキサバン液体製剤

Country Status (18)

Country Link
US (2) US9452134B2 (https=)
EP (1) EP2900217A1 (https=)
JP (1) JP6248112B2 (https=)
KR (1) KR102035373B1 (https=)
CN (1) CN104736142B (https=)
AU (1) AU2013323435C1 (https=)
BR (1) BR112015005995A2 (https=)
CA (1) CA2885899A1 (https=)
HK (1) HK1212900A1 (https=)
IL (1) IL237804A0 (https=)
IN (1) IN2015DN01902A (https=)
MX (1) MX358097B (https=)
MY (1) MY179191A (https=)
NZ (1) NZ630763A (https=)
PH (1) PH12015500590B1 (https=)
RU (1) RU2660358C2 (https=)
SG (2) SG11201501743UA (https=)
WO (1) WO2014052678A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2907507A1 (en) * 2014-02-17 2015-08-19 Sandoz Ag Pharmaceutical composition comprising apixaban
WO2017221209A1 (en) 2016-06-23 2017-12-28 Lupin Limited Pharmaceutical formulations of apixaban
PT3781132T (pt) * 2018-04-16 2024-05-16 Pfizer Formulações de apixabano
BR112021002675A2 (pt) 2018-08-14 2021-05-11 Jiangsu Hengrui Medicine Co., Ltd. composições farmacêuticas, métodos para preparar as referidas composições e uso das mesmas
HUE073416T2 (hu) 2019-11-13 2026-01-28 Unison Pharmaceuticals Pvt Ltd Az apixaban orálisan dezintegrálódó gyógyszerkészítményei
WO2022123074A1 (en) 2020-12-13 2022-06-16 Dafechem Ltd Liquid apixaban formulation in small dose volume
CN113384526A (zh) * 2021-08-03 2021-09-14 合肥医工医药股份有限公司 一种稳定的阿哌沙班口服溶液制剂及其制备方法
NL2029536B1 (en) 2021-10-27 2023-05-26 Pharma Data S A Apixaban suspension and preparation method
US12214075B2 (en) 2021-10-27 2025-02-04 Pharma-Data Research And Development Single Member S.A. Apixaban suspension and preparation method
US12194028B2 (en) 2022-03-09 2025-01-14 Slayback Pharma Llc Stable pharmaceutical compositions of apixaban
WO2023218482A1 (en) 2022-05-09 2023-11-16 Syri Research Private Limited Liquid oral formulation of apixaban or pharmaceutically acceptable salt thereof
US12213972B2 (en) * 2022-07-27 2025-02-04 Slayback Pharma Llc Stable pharmaceutical compositions of apixaban
EP4658238A1 (en) * 2023-01-30 2025-12-10 TAP Pharmaceuticals AG Liquid pharmaceutical formulations of apixaban
US11833138B1 (en) 2023-01-30 2023-12-05 Tap Pharmaceuticals Ag Liquid pharmaceutical formulations of apixaban
EP4450064A1 (en) 2023-04-14 2024-10-23 Novick BioSciences Private Limited Apixaban compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763449A (en) * 1996-08-07 1998-06-09 Ascent Pediatrics, Inc. Pleasant-tasting aqueous liquid composition of a bitter-tasting drug
GEP20053427B (en) 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CA2461202C (en) * 2001-09-21 2011-07-12 Donald Pinto Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
JP2008531556A (ja) * 2005-02-25 2008-08-14 バイオマリン ファーマシューティカル インコーポレイテッド 室温で安定な水性の液状薬学的組成物
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
CA2712120A1 (en) * 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
WO2010132711A1 (en) * 2009-05-13 2010-11-18 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
SMT202000093T1 (it) * 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
IN2012DN06587A (https=) * 2010-02-25 2015-10-23 Bristol Myers Squibb Co
EP2484775A1 (de) 2011-02-07 2012-08-08 Siemens Healthcare Diagnostics Products GmbH Heparin-insensitives Verfahren zur Bestimmung von direkten Gerinnungsfaktorinhibitoren
RU2638155C1 (ru) * 2016-02-29 2017-12-12 Общество С Ограниченной Ответственностью "Сай Фарма" Производные бензо[d]изоксазола и их применение

Similar Documents

Publication Publication Date Title
JP2015531377A5 (https=)
RU2015115127A (ru) Жидкие лекарственные композиции апиксабана
ES2545395T3 (es) Asociación de ivermectina con brimonidina para el tratamiento o prevención de la rosácea
AU2021229177B2 (en) Diacerein or rhein topical formulations and uses thereof
AR082024A1 (es) Formulacion de anticuerpo contra ox40l humano
AR103653A1 (es) Complejos de acetato de abiraterona, proceso para prepararlos y composiciones farmacéuticas que los contienen
RU2016103753A (ru) Лечение воспалительных повреждений при розациа с помощью ивермектина
JP2016503030A5 (https=)
AR073793A1 (es) Formulacion farmaceutica liquida que contiene paracetamol. excipiente liquido
WO2012083138A3 (en) Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds
RU2014101990A (ru) Жидкая фармацевтическая композиция, включающая нитизинон
EP3277283B1 (en) Sildenafil sublingual spray formulations
CN113301884A (zh) 非水性化疗口服悬浮液
CN101856329A (zh) 苯甲酸利扎曲普坦口腔喷雾剂
US9370518B2 (en) Sildenafil sublingual spray formulation
RU2021102950A (ru) Твердые фармацевтические композиции для лечения вируса гепатита с
JP2015518000A5 (https=)
US20200230082A1 (en) Topical acetaminophen formulations for itch relief
US10512625B2 (en) Diacerein or rhein topical formulations and uses thereof
AR086252A1 (es) Formulacion topica que comprende dipropionato de beclometasona como ingrediente activo
EP3218060B1 (en) Sprayable analgesic compositions
US10154984B2 (en) Diacerein or Rhein topical formulations and uses thereof
JP5992293B2 (ja) 眼科用剤
EP3481370B1 (en) Pharmaceutical composition comprising benzydamine